Document Detail

Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome.
Jump to Full Text
MedLine Citation:
PMID:  20421938     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is a predictor of mortality in critical illness. Severe malaria (SM) is associated with decreased NO bioavailability, but the contribution of ADMA to the pathogenesis of impaired NO bioavailability and adverse outcomes in malaria is unknown. In adults with and without falciparum malaria, we tested the hypotheses that plasma ADMA would be: 1) increased in proportion to disease severity, 2) associated with impaired vascular and pulmonary NO bioavailability and 3) independently associated with increased mortality. We assessed plasma dimethylarginines, exhaled NO concentrations and endothelial function in 49 patients with SM, 78 with moderately severe malaria (MSM) and 19 healthy controls (HC). Repeat ADMA and endothelial function measurements were performed in patients with SM. Multivariable regression was used to assess the effect of ADMA on mortality and NO bioavailability. Plasma ADMA was increased in SM patients (0.85 microM; 95% CI 0.74-0.96) compared to those with MSM (0.54 microM; 95%CI 0.5-0.56) and HCs (0.64 microM; 95%CI 0.58-0.70; p<0.001). ADMA was an independent predictor of mortality in SM patients with each micromolar elevation increasing the odds of death 18 fold (95% CI 2.0-181; p = 0.01). ADMA was independently associated with decreased exhaled NO (r(s) = -0.31) and endothelial function (r(s) = -0.32) in all malaria patients, and with reduced exhaled NO (r(s) = -0.72) in those with SM. ADMA is increased in SM and associated with decreased vascular and pulmonary NO bioavailability. Inhibition of NOS by ADMA may contribute to increased mortality in severe malaria.
Authors:
Tsin W Yeo; Daniel A Lampah; Emiliana Tjitra; Retno Gitawati; Christabelle J Darcy; Catherine Jones; Enny Kenangalem; Yvette R McNeil; Donald L Granger; Bert K Lopansri; J Brice Weinberg; Ric N Price; Stephen B Duffull; David S Celermajer; Nicholas M Anstey
Related Documents :
18589138 - The burden of chronic kidney disease in long-term liver transplant recipients.
18635188 - Pravastatin reduces the risk for cardiovascular disease in japanese hypercholesterolemi...
11742888 - Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase def...
17855638 - Age affects outcomes in chronic kidney disease.
20664188 - Klinefelter's syndrome: a clinical and therapeutical update.
10938958 - Clinical significance of leukoreduktion of blood components.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2010-04-22
Journal Detail:
Title:  PLoS pathogens     Volume:  6     ISSN:  1553-7374     ISO Abbreviation:  PLoS Pathog.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-27     Completed Date:  2010-06-25     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  101238921     Medline TA:  PLoS Pathog     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e1000868     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Arginine / analogs & derivatives*,  blood
Biological Availability
Chromatography, High Pressure Liquid
Endothelium, Vascular / metabolism
Enzyme-Linked Immunosorbent Assay
Female
Humans
Malaria, Falciparum / metabolism*,  mortality,  pathology
Male
Nitric Oxide / metabolism*,  pharmacokinetics
Nitric Oxide Synthase / antagonists & inhibitors
Prognosis
Grant Support
ID/Acronym/Agency:
091625//Wellcome Trust; AI041764/AI/NIAID NIH HHS; AI55982/AI/NIAID NIH HHS; ICRG GR071614MA//Wellcome Trust
Chemical
Reg. No./Substance:
0/dimethylarginine; 31C4KY9ESH/Nitric Oxide; 94ZLA3W45F/Arginine; EC 1.14.13.39/Nitric Oxide Synthase
Comments/Corrections
Erratum In:
PLoS Pathog. 2010;6(5). doi: 10.1371/annotation/e49842d3-ea72-45a4-93d4-2f494baee962

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS Pathog
Journal ID (publisher-id): plos
Journal ID (pmc): plospath
ISSN: 1553-7366
ISSN: 1553-7374
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Received Day: 30 Month: 11 Year: 2009
Accepted Day: 22 Month: 3 Year: 2010
collection publication date: Month: 4 Year: 2010
Print publication date: Month: 4 Year: 2010
Electronic publication date: Day: 22 Month: 4 Year: 2010
Volume: 6 Issue: 4
E-location ID: e1000868
ID: 2858698
PubMed Id: 20421938
Publisher Id: 09-PLPA-RA-2175R3
DOI: 10.1371/journal.ppat.1000868

Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome Alternate Title:Asymmetrical Dimethylarginine and Malaria
Tsin W. Yeo1*
Daniel A. Lampah2
Emiliana Tjitra3
Retno Gitawati3
Christabelle J. Darcy1
Catherine Jones1
Enny Kenangalem2
Yvette R. McNeil1
Donald L. Granger4
Bert K. Lopansri45
J. Brice Weinberg6
Ric N. Price178
Stephen B. Duffull9
David S. Celermajer10
Nicholas M. Anstey18
James W. Kazuraedit1 Role: Editor
1International Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
2Menzies School of Health Research-National Institute of Health Research and Development Research Program, and District Ministry of Health, Timika, Papua, Indonesia
3National Institute of Health Research and Development, Jakarta, Indonesia
4Division of Infectious Diseases, University of Utah and VA Medical Centers, Salt Lake City, Utah, United States of America
5Division of Infectious Disease, Loyola University Medical Center, Maywood, Illinois, United States of America
6Division of Hematology-Oncology, Duke and VA Medical Centers, Durham, North Carolina, United States of America
7Centre for Vaccinology & Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom
8Division of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia
9School of Pharmacy, University of Otago, Dunedin, New Zealand
10Department of Medicine, University of Sydney and Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Case Western Reserve University, United States of America
Correspondence: * E-mail: tsin.yeo@menzies.edu.au
Contributed by footnote: Conceived and designed the experiments: TWY ET RG DLG BKL JBW RNP SBD DSC NMA. Performed the experiments: TWY DAL ET RG CJD CJ EK YRM NMA. Analyzed the data: TWY RNP NMA. Wrote the paper: TWY DAL ET RG CJD CJ EK YRM DLG BKL JBW RNP SBD DSC NMA.

Introduction

Plasmodium falciparum causes ?1 million deaths annually [1], [2]. Despite rapid parasite clearance with the anti-parasitic drug artesunate, the mortality rate in severe malaria remains high [3], [4]. Endothelial activation, parasite sequestration, impaired microvascular perfusion and dysregulated inflammatory responses are all thought to contribute to severe and fatal malaria [5]?[9]. Increased understanding of these pathogenic mechanisms may identify targets for adjunctive therapies to further improve outcomes.

Severe malaria is associated with impaired nitric oxide (NO) bioavailability and blood mononuclear cell NO synthase (NOS) type 2 expression in both children [10], [11] and adults [6]. The concentrations of L-arginine, the substrate for NO production by all three NOS isoforms [12], are low in children and adults with severe malaria and likely contribute to the decreased NO production found in severe disease [6], [10], [13]. However, in adults with moderately severe malaria, L-arginine concentrations are at least as low as those seen with severe malaria, yet there is no impairment of vascular and pulmonary NO bioavailability as found in severe disease [6]. This suggests that factors other than substrate limitation contribute to impaired NO bioavailability in severe malaria.

Asymmetrical dimethylarginine (ADMA) is a non-specific endogenous NOS inhibitor which decreases vascular function in cardiovascular and renal disease [14], [15]. Protein-arginine-methyltransferases methylate arginine residues in proteins and ADMA is released when these proteins undergo degradation [14]. ADMA is primarily eliminated by the enzyme dimethylarginine-dimethylaminohydrolase-1 (DDAH-1) in the liver and kidney, with ?20% being excreted in the urine [16]. In adult sepsis, elevated ADMA is independently associated with increased mortality, a likely consequence of non-specific inhibition of homeostatic NO production [17], [18]. Increased protein catabolism with hepatic and renal dysfunction in severe malaria has the potential to increase ADMA and impair NO production, but the importance of ADMA in the pathogenesis of malaria is currently unknown. Clarification of the role of ADMA in malaria is of particular importance given a recent genome-wide association study in children linking DDAH polymorphisms with risk of severe malaria [19], and the potential for the parasite as well as host to produce ADMA [20].

Acute lung injury is a common but little-studied complication of severe falciparum malaria associated with high mortality [21]. In sepsis and critical illness, acute lung injury and mortality are associated with decreased total and pulmonary NO [22], [23]. Pulmonary diffusion capacity and exhaled NO concentrations are both reduced in severe malaria [6], [24], however the causative factors have not been identified. The role of ADMA in impairing pulmonary NO bioavailability in severe malaria, or indeed any critical illness, is not known.

In a prospective longitudinal study of Indonesian adults with malaria, we evaluated the hypotheses that concentrations of methylated arginines are independently associated with a) disease severity, b) reduced exhaled NO and vascular NO bioavailability and c) increased mortality.


Results
Patients

We measured asymmetrical dimethylarginine (ADMA), symmetrical dimethylarginine (SDMA) and L-arginine in 49 patients with severe malaria, 78 with moderately severe malaria and 19 healthy controls. In the SM patients, 20 patients had only one criterion for severe disease (coma in 14, hyperbilirubinemia in 4, respiratory distress in 2) with the remainder having >1 criteria. In total, 34 of the patients with SM were treated with intravenous artesunate and the remaining 15 received intravenous quinine [6]. All of the 78 MSM patients were treated with quinine with the exception of one who received artesunate. Exhaled NO concentrations (FeNO) could not be measured in those with coma, but were possible in 48% (11/23) of non-comatose SM patients, 88% (69/78) of MSM patients and 100% (19/19) of HCs. RH-PAT index was measured in all patients with malaria as well as HC. There were eight deaths among the patients with SM, and none in the MSM patients. Repeat RH-PAT and venous blood measurements were only performed in one and four of the eight fatal cases respectively. Baseline characteristics of study participants are summarized in Table 1.

ADMA, SDMA, L-arginine/ADMA ratio, ADMA/SDMA ratio and clinical disease

ADMA and SMDA concentrations were increased in SM patients (0.85 ?M; 95% CI 0.74?0.96 and 1.67 ?M; 95% CI 1.24?2.09 respectively) compared to those with MSM (0.54 ?M; 95%CI 0.5?0.56 and 0.58 ?M; 95%CI 0.54?0.63) and HC (0.64 ?M; 95%CI 0.58?0.70 and 0.53 ?M; 95%CI 0.47?0.59); ANOVA p<0.001 for both ADMA and SDMA, Table 2, Figure 1A and 1B. L-arginine concentrations were significantly higher in HCs compared to patients with MSM and SM, with the L-arginine/ADMA ratio decreasing with increasing disease severity (p<0.001; Table 2).

ADMA, SDMA, L-arginine/ADMA ratio and exhaled nitric oxide concentrations

Exhaled nitric oxide concentration (FeNO) was significantly decreased in SM patients compared to MSM and HC; (Table 2). FeNO was inversely correlated with plasma ADMA concentration (rs?=??0.31, p?=?0.003; Table 3) in all malaria patients, and in the subgroup of 11 patients with SM (rs?=??0.72, p?=?0.01; Table 3). FeNO also correlated inversely with HRP2 concentration (rs?=??0.51, p<0.001) in malaria patients, but not in the SM group. FeNO remained inversely associated with ADMA, after adjusting for disease severity, creatinine and HRP2. FeNO was not associated with SDMA, the L-arginine/ADMA ratio, plasma hemoglobin or arginase.

ADMA, SDMA, L-arginine/ADMA ratio and endothelial function

As reported previously, the RH-PAT index was significantly lower in SM patients compared to those with MSM and controls (p<0.001) Table 2. In all malaria patients, there were moderate inverse associations between RH-PAT index and ADMA (rs?=??0.32; p<0.001; Table 3) and SDMA (rs?=??0.35; p<0.001) concentrations. After adjusting for factors previously shown to be associated with RH-PAT index including plasma hemoglobin [6], [7], [25], the inverse association with ADMA remained significant, with the final model including both ADMA and cell free hemoglobin (r?=?0.40). In contrast, the L-arginine/ADMA ratio was not associated with the RH-PAT index. Longitudinally there was no association between the RH-PAT index and ADMA concentration or L-arginine/ADMA ratio in SM patients.

ADMA, SDMA, L-arginine/ADMA ratio and markers of endothelial activation

Patients with SM had significantly elevated plasma concentrations of Ang-2, ICAM-1 and E-selectin compared to those with MSM and HC; Table 2. Angiopoietin-2 and ICAM-1 were significantly correlated with both ADMA (rs?=?0.48 and 0.42 respectively; p<0.001; Table 3), and SDMA (rs?=?0.54 and 0.52; p<0.001), and this was also apparent in the subgroup of SM patients; Table 3. ADMA remained independently associated with Ang-2 and ICAM-1 after adjusting for confounding factors, including creatinine, plasma hemoglobin, parasite biomass and disease severity.

There was no significant correlation between ADMA or SDMA with E-selectin, and none between the L-arginine/ADMA ratio and Ang-2, ICAM-1 and E-selectin.

ADMA, SDMA, L-arginine/ADMA ratio and biomarkers of severity

The plasma creatinine, total bilirubin, P. falciparum histidine rich protein 2 (HRP2) and venous lactate were increased in SM compared to MSM (Table 2). In all patients with malaria, there were correlations between ADMA and SDMA with creatinine (rs?=?0.45; p<0.001; rs?=?0.69; p<0.001; Table 3), total bilirubin (rs?=?0.32; p<0.001; rs?=?0.36; p<0.001; Table 3), HRP2 (rs?=?0.46; p<0.001; rs?=?0.62; p<0.001; Table 3) and lactate (rs?=?0.3; p?=?0.01; rs?=?0.29, p?=?0.02; Table 3). The associations remained significant in SM patients for each of these biomarkers of disease severity except for venous lactate (Table 3). There was no association between L-arginine/ADMA ratio and any biomarker. TNF was only measured in the SM patients, and was associated with SDMA (rs?=?0.52; p?=?0.001), but not with ADMA (p?=?0.06).

ADMA, SDMA, L-arginine/ADMA ratio and mortality

In SM patients, ADMA and SDMA concentrations were significantly higher in the 8 patients who died (1.28 ?M; 95%CI 0.88?1.74 and 3.76 ?M; 95%CI 1.88?5.56, respectively) compared to the 41 survivors (0.77 ?M; 95%CI 0.64?0.84 and 1.27 ?M; 95%CI 0.99?1.54, respectively; p<0.001; Figure 1A and 1B).

Each micromolar increase in ADMA and SDMA concentrations was associated with an 18-fold (OR 18.8 95% CI 2.0?181; p?=?0.01) and three-fold (OR 3.0; 95% CI 1.5?6.2; p?=?0.002) increased risk of death, respectively. ADMA but not SDMA remained a significant risk factor for death after adjusting for other confounding factors, such as Ang-2, creatinine, parasite biomass, bilirubin, base deficit and lactate. A final model predicting a fatal outcome included ADMA, Ang-2, HRP2 and creatinine (Table 4). The L-arginine/ADMA ratio was not associated with risk of death.

The prognostic value of ADMA in predicting a fatal outcome was measured by the area under the receiver operating curve (ROC). ADMA (AUROC 0.85; 95% CI 0.71?0.99; Figure 2) was comparable to other reliable prognostic indicators, including Ang-2 (AUROC 0.84; 95% CI 0.71?0.96), HRP2 (AUROC 0.86; 95% CI 0.73?0.94), base deficit (AUROC 0.73; 95% CI 0.53?0.92), and TNF (AUROC 0.71; 95% CI 0.43?0.98), and a better predictor of fatal outcome than venous blood lactate (AUROC 0.63; 95%CI 0.41?0.83; p?=?0.003).

Longitudinal Course of ADMA, SDMA and L-arginine/ADMA ratio

In patients with severe malaria, there was no significant change in ADMA (Figure 3A) or SDMA concentrations during the course of hospitalization among the overall group, survivors or those with a fatal outcome. Among survivors, there was a daily increase in L-arginine/ADMA (??=?9.1, p<0.001; Figure 3B) but no increase in those who died.


Discussion

ADMA is increased in severe falciparum malaria and is an independent predictor of mortality. Indeed ADMA was a better predictor of death than blood lactate, previously shown to be a reliable prognostic indicator of increased mortality in severe malaria [26]. Our study demonstrated that elevated plasma ADMA concentrations are independently associated with decreased exhaled NO concentrations, impaired vascular NO bioavailability, increased endothelial activation and parasite biomass. To our knowledge this is the first demonstration of a relationship between increased ADMA and impaired exhaled NO in any critical illness. Taken together, these findings suggest that ADMA, an endogenous inhibitor of all three nitric oxide synthase (NOS) isoforms, reduces NO bioavailability in at least two organ systems and may contribute to increased mortality in falciparum malaria.

In critically ill patients, elevated ADMA concentrations are likely to result from increased production and reduced elimination. The elevation in both ADMA and SDMA may result from increased host production of methylated arginines in severe malaria. The majority of circulating ADMA is taken up by the liver before being metabolized by dimethylarginine-dimethylaminohydrolase-1 (DDAH-1); approximately 20% is excreted unchanged in the urine [16]. Hepatic blood flow is known to be significantly impaired in severe malaria [27]. The correlation of bilirubin and creatinine with increased ADMA, suggests that similar to sepsis [28], decreased hepatic and renal elimination may also increase ADMA concentrations in severe malaria. The large parasite biomass in severe malaria may also be a potential source of ADMA, with Plasmodium falciparum possessing protein arginine methyltransferases capable of producing ADMA [20]. The significant independent correlation between parasite biomass and ADMA on admission suggests this may be occurring in vivo, although the persistently elevated levels in severe malaria after commencement of anti-malarial therapy suggest the importance of altered host production and clearance in the post-treatment period. Increased clearance due to increases in either hepatic blood flow or DDAH activity may explain the decreased ADMA concentrations in patients with moderately severe malaria. There are no clinical studies to date documenting increased DDAH activity in mild inflammatory diseases, but hepatic blood flow is known to be significantly increased in acute uncomplicated falciparum malaria compared to patients with severe disease and healthy individuals [27]. The converse may also be true, with lower plasma ADMA concentrations potentially increasing vascular NO bioavailability in moderately severe malaria [14], and possibly contributing to elevated hepatic blood flow.

The loss of DDAH-1 function in a murine model of sepsis increased ADMA, reduced NO signaling, and worsened vascular pathophysiology including endothelial function [29]. In human severe sepsis, a polymorphism in the DDAH-2 enzyme increased ADMA levels which were associated with increased severity of organ failure and early septic shock [30]. Recently, a genome-wide association study in children found that a polymorphism in the gene encoding DDAH-1 was associated with an increased likelihood of severe malaria [19]. These studies indicate that altered DDAH function may be a contributor to organ damage and increased mortality in severe malaria as well as in other critical illnesses.

SDMA does not inhibit NOS, but competes with plasma L-arginine for intracellular uptake by the cationic amino acid transporters (CAT). Unlike ADMA, it is not metabolized by DDAH and is almost exclusively eliminated by the kidneys [16]. In chronic disease SDMA has recently been shown to be an independent predictor for major cardiovascular events in certain chronic diseases [31]. We find that in malaria, SDMA concentrations are associated with mortality and decreased vascular bioavailability on univariate analysis, but not after adjusting for renal function. While the association between SDMA and disease severity is likely to reflect the degree of renal impairment and SDMA retention, it is possible that retained SDMA may also contribute to decreased NO bioavailability in severe malaria.

In critically ill adults with organ failure and severe sepsis, ADMA concentrations are associated with increased all-cause mortality and the severity of organ failure [17], [30]. Investigators have hypothesized that this may result from non-selective inhibition by ADMA of all three isoforms of NOS, particularly homeostatic NOS3 (endothelial NOS) [18]. This is similar to the postulated mechanism to explain the increased mortality with use of NG-monomethyl-arginine (NMMA), another non-specific NOS inhibitor, in a phase 3 clinical trial of sepsis [32]. In falciparum malaria, systemic NO production is impaired in severe disease and hypoargininemia is likely to be a contributing cause [6], [10], [11], [13]. Exhaled and vascular NO are both reduced in adults with severe malaria [6], but not in moderately severe malaria (MSM) despite similar degrees of hypoargininemia [6]. This may be explained by the higher ADMA in severe malaria and a greater competitive inhibition of NOS in SM compared to MSM, similar to clinical studies of healthy volunteers in which ADMA infusion reduced blood flow [15], [33]. In mouse studies, ADMA infusion alone reduces splenic blood perfusion, but when combined with hypoargininemia, causes a reduction in renal, hepatic and splenic blood flow with organ damage [34]. Regulation of microcirculatory flow is dependent on pre-capillary arteriolar vasodilatory responses which in turn are critically dependent on NO production [35], with both likely to be decreased by ADMA in SM. By decreasing functional capillary density, ADMA could further impair microcirculatory function already compromised by parasite sequestration in capillaries and post-capillary venules [36].

We have previously shown that hemolysis-related NO quenching by cell-free hemoglobin is associated with reduced vascular NO bioavailability in severe malaria [25]. In malaria, increased ADMA and cell-free hemoglobin were independently related to endothelial dysfunction, suggesting that inhibition of NOS and NO quenching both reduce vascular NO bioavailability.

NO has multiple regulatory functions that maintain endothelial quiescence in vitro, including inhibition of endothelial Weibel-Palade body (WPB) exocytosis and ICAM-1 expression [37], [38]. Plasma concentrations of angiopoietin-2 (Ang-2), an angiogenic factor stored in WPBs, predict increased mortality in malaria [7], and ICAM-1 is a major endothelial adhesion receptor mediating cytoadherence of parasitized red cells and microvascular sequestration [5]. We demonstrate that ADMA levels correlate with increased Ang-2, but the association between ADMA and increased mortality is independent of Ang-2, suggesting effects of NO inhibition in addition to increased WPB exocytosis.

Acute lung injury is a complication of severe malaria in adults associated with a high mortality rate [21], [24]. Gas transfer at the alveolar-capillary membrane and exhaled NO are both decreased in severe falciparum malaria [6], [24]. In an animal model of sepsis?associated pulmonary injury, non-selective NOS inhibition causes increased lung edema [39]. Clinical studies have shown decreased pulmonary NO concentrations in patients with acute respiratory distress syndrome, as well as an association between decreased NO production and a worse outcome in acute lung injury [22], [23]. The lung is a major source of ADMA and increased concentrations are associated with pulmonary arterial hypertension [40], [41]. In severe malaria, both ADMA and parasite biomass are strongly inversely associated with exhaled NO concentrations, suggesting that both factors impair pulmonary NO production in severe disease.

There are several limitations in our study. Measurement of exhaled NO was not possible in patients with coma and was possible in only half of severe malaria patients without coma. Our results may therefore not reflect the relationship between ADMA and exhaled NO in all syndromes of severe malaria. In patients who died, only 4 of 8 had at least one repeat blood sample, and the longitudinal data may not truly reflect the course of the methylated arginines in fatal cases. RH-PAT index is at least 50% dependent on endothelial NO release [42], but we cannot exclude an effect of ADMA on other vasodilators such as prostacyclin and endothelium-derived hyperpolarizing factor. Although we have measured plasma ADMA concentrations, the effects of ADMA are intracellular. Nevertheless, in vitro studies with endothelial cells have shown that increasing extracellular ADMA results in five-fold increases in intracellular concentrations. This suggest that intracellular concentrations of ADMA in severe malaria may be higher, and may be adequate for meaningful inhibition of for all three NOS isoforms (IC50s ?2-5?M) [43]. The observational nature of the study does not allow us to conclude with certainty a direct role for ADMA in the pathophysiology of severe malaria. While the association of ADMA with mortality may reflect impaired renal and hepatic function, it remained significant after adjusting for these factors in a multivariable model. Furthermore, increased ADMA from impaired hepatic and/or renal clearance is not just a marker of organ dysfunction in critical illness, with retained ADMA having functional consequences on NOS activity.

In summary, the endogenous non-selective NOS inhibitor ADMA is elevated in SM and is an independent risk factor for mortality. ADMA is also associated with decreased FeNO and vascular NO bioavailability, as well as increased endothelial activation and parasite biomass. Therapies which increase NO bioavailability or which diminish ADMA levels represent rational approaches for interventional trials of adjunctive therapy in severe malaria.


Methods
Study site and patients

The study was conducted at Mitra Masyarakat Hospital, Timika, Papua, Indonesia, a region with unstable transmission of multidrug resistant malaria [44], [45]. Written informed consent was obtained from all patients, if they were comatose or too ill, consent was obtained from relatives. The Ethics Committees of the National Institute of Health Research and Development, Indonesia, and Menzies School of Health Research, Australia approved the study.

Patients were ?18 years old with moderately-severe (MSM) or severe (SM) Plasmodium falciparum malaria without P. vivax infection and with a hemoglobin level >60 g/L who had been prospectively enrolled in a study of endothelial dysfunction and exhaled NO [6]. Previous results from this study group have been published [6], [7], [13], [25]. Briefly, SM was defined as P. falciparum parasitemia and ?1 modified WHO criterion of severity (excluding severe anemia). MSM was defined as fever within the preceding 48 hours, >1,000 asexual P. falciparum parasites/?L, no WHO warning signs or severe malaria criteria and a requirement for inpatient parenteral therapy because of inability to tolerate oral treatment. Healthy controls (HC) were non-related hospital visitors with no history of fever in last 48 hours, intercurrent illness or smoking in last 12 hours, or evidence of parasitemia [6]. Standardized history and physical examination were documented. Heparinized blood was collected daily, centrifuged within 30 minutes of collection and plasma stored at ?70?C. Parasite counts were determined by microscopy. Hemoglobin, biochemistry, acid-base parameters and lactate were measured with a bedside analyser (i-STAT Corp). Patients were treated with anti-malarials and antibiotics using standard national protocols as previously described [6].

L-arginine, asymmetrical dimethylarginine and symmetrical dimethylarginine

Solid phase extraction (SPE) of amino acids was followed by derivatisation with Accq-Fluor and separation on a Gemini-NX column at pH 9 [46]. The SPE method gives absolute recoveries of >80% for ADMA and symmetrical dimethylarginine (SDMA) and average relative recoveries of 102% for ADMA and 101% for SDMA. The HPLC method gives intra-assay RSDs of 2.1% and 2.3% and inter-assay RSDs of 2.7% and 3.1% for ADMA and SDMA respectively [46].

Cell-free hemoglobin, cytokines, endothelial activation, arginase and L-arginine

Plasma concentrations of cell-free hemoglobin and the endothelial activation markers, ICAM-1, E-selectin and angiopoietin-2 were measured by ELISA as previously reported in this population [6], [7], [25]. Total parasite biomass was quantified by measuring plasma histidine rich protein-2 (HRP2) by ELISA [6], plasma arginase by a radiometric method [6] and plasma TNF concentrations by flow cytometry, as previously reported [7].

Endothelial function and pulmonary nitric oxide

Endothelial function was measured non-invasively using peripheral arterial tonometry (EndoPAT) by the change in digital pulse wave amplitude in response to reactive hyperemia, giving a RH-PAT Index as reported previously [6]. The RH-PAT index is at least 50% dependent on endothelial NO production [42]. Endothelial function was measured daily until death or discharge, or until the RH-PAT index was above an a priori cutoff (1.67) for two consecutive days [13]. Fractional concentrations of exhaled NO were measured by NO analyser (Aerocrine), as previously described, using American Thoracic Society guidelines and a flow rate of 250 ml/sec [6].

Statistical methods

Statistical analysis was performed with STATA 9.2 software. Intergroup differences were compared by ANOVA or Kruskal-Wallis test, where appropriate. Pearson's or Spearman's correlation coefficients were determined depending on normality of distributions. Multiple stepwise linear regression was used to adjust for confounding variables. Longitudinal associations were assessed by mixed effects modeling using generalized estimating equations. Logistic regression was used to determine the association between death and ADMA concentrations. Variables hypothesized, as well as those shown in previous publications [6], [7], [25], to contribute to mortality, pulmonary NO and endothelial pathology were included in a multiple regression model if p<0.05 on univariate analysis and retained if they remained significant. Goodness-of-fit was assessed by the Hosmer-Lemeshow goodness of fit test and independent variables tested for interactions. The prognostic utility of continuous variables was measured using the area under the receiver operating curves (ROCs) and its 95% confidence intervals were calculated. A two-sided value of p<0.05 was considered significant.


Notes

The authors have declared that no competing interests exist.

The study was funded National Health and Medical Research Council of Australia (NHMRC ICRG ID 283321, Program Grants 290208 and 496600, and Practitioner Fellowship to Nicholas M. Anstey), the Wellcome Trust (ICRG GR071614MA and Career Development Award to Ric Price [074637]), VA Research Service, the National Institutes of Health (AI55982 and AI041764) and the Tudor Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We thank Govert Waramori, Kim Piera, Marlini Malisan, Margaretha Ferre, Ferryanto Chalfein, Prayoga, Roesmini, Yoshi Elvi for nursing, technical and logistical assistance; Mitra Masyarakat Hospital staff for clinical care and Jeanne Rini, Paulus Sugiarto, Mauritz Okeseray, and Lembaga Pengembangan Masyarakat Amungme Kamoro for support. Purified PfHRP2 protein was kindly supplied by David Sullivan.


References
1. Snow RW,Guerra CA,Noor AM,Myint HY,Hay SI. Year: 2005The global distribution of clinical episodes of Plasmodium falciparum malaria.Nature43421421715759000
2. World Health Organization (2008) World Malaria Report.
3. Day N,Dondorp AM. Year: 2007The Management of Patients with Severe Malaria.Am J Trop Med Hyg77Suppl 6293518165472
4. The SEAQUAMAT Trial GroupYear: 2005Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.Lancet36671772516125588
5. Turner GD,Morrison H,Jones M,Davis TM,Looareesuwan S,et al. Year: 1994An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration.Am J Pathol145105710697526692
6. Yeo TW,Lampah DA,Gitawati R,Tjitra E,Kenangalem E,et al. Year: 2007Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria.J Exp Med2042693270417954570
7. Yeo TW,Lampah DA,Gitawati R,Tjitra E,Kenangalem E,et al. Year: 2008Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria.Proc Natl Acad Sci U S A105170971710218957536
8. Minigo G,Woodberry T,Piera KA,Salwati E,Tjitra E,et al. Year: 2009Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria.PLoS Pathog5e1000402 doi:10.1371/journal.ppat.1000402. 19390618
9. Lovegrove FE,Tangpukdee N,Opoka RO,Lafferty EI,Rajwans N,et al. Year: 2009Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children.PLoS ONE4e4912 doi:10.1371/journal.pone.0004912. 19300530
10. Lopansri BK,Anstey NM,Weinberg JB,Stoddard GJ,Hobbs MR,et al. Year: 2003Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production.Lancet36167667812606182
11. Anstey NM,Weinberg JB,Hassanali MY,Mwaikambo ED,Manyenga D,et al. Year: 1996Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression.J Exp Med1845575678760809
12. Hibbs J,Vavrin Z,Taintor R. Year: 1987L-arginine is required for the expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells.J Immunol1385502432129
13. Yeo TW,Lampah DA,Gitawati R,Tjitra E,Kenangalem E,et al. Year: 2008Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations.J Infect Dis19860260818605903
14. Vallance P,Leiper J. Year: 2004Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.Arterioscler Thromb Vasc Biol241023103015105281
15. Vallance P,Leone A,Calver A,Collier J,Moncada S. Year: 1992Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.Lancet3395725751347093
16. Teerlink T. Year: 2005ADMA metabolism and clearance.Vasc Med10Suppl 1S738116444872
17. Nijveldt RJ,Teerlink T,Van Der Hoven B,Siroen MP,Kuik DJ,et al. Year: 2003Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.Clin Nutr22233012553946
18. Nijveldt RJ,Teerlink T,van Leeuwen PA. Year: 2003The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.Clin Nutr229910412553957
19. Jallow M,Teo YY,Small KS,Rockett KA,Deloukas P,et al. Year: 2009Genome-wide and fine-resolution association analysis of malaria in West Africa.Nat Genet41657665
20. Fan Q,Miao J,Cui L. Year: 2009Characterization of protein arginine methyltransferase I from Plasmodium falciparum.Biochem J42110711819344311
21. Taylor WR,White NJ. Year: 2002Malaria and the lung.Clin Chest Med2345746812092039
22. Brett SJ,Evans TW. Year: 1998Measurement of endogenous nitric oxide in the lungs of patients with the acute respiratory distress syndrome.Am J Respir Crit Care Med1579939979517623
23. McClintock DE,Ware LB,Eisner MD,Wickersham N,Thompson BT,et al. Year: 2007Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury.Am J Respir Crit Care Med17525626217082495
24. Maguire GP,Handojo T,Pain MC,Kenangalem E,Price RN,et al. Year: 2005Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in papua, Indonesia.J Infect Dis1921966197416267769
25. Yeo TW,Lampah DA,Tjitra E,Gitawati R,Kenangalem E,et al. Year: 2009Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria.J Infect Dis2001522152919803726
26. Day NP,Phu NH,Mai NT,Chau TT,Loc PP,et al. Year: 2000The pathophysiologic and prognostic significance of acidosis in severe adult malaria.Crit Care Med281833184010890629
27. Molyneux ME,Looareesuwan S,Menzies IS,Grainger SL,Phillips RE,et al. Year: 1989Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria.Am J Trop Med Hyg404704762729505
28. Richir MC,Bouwman RH,Teerlink T,Siroen MP,de Vries TP,et al. Year: 2008The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.JPEN J Parenter Enteral Nutr3261362118974239
29. Leiper J,Nandi M,Torondel B,Murray-Rust J,Malaki M,et al. Year: 2007Disruption of methylarginine metabolism impairs vascular homeostasis.Nat Med1319820317273169
30. O'Dwyer MJ,Dempsey F,Crowley V,Kelleher DP,McManus R,et al. Year: 2006Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study.Crit Care10R13917002794
31. Wang Z,Tang WH,Cho L,Brennan DM,Hazen SL. Year: 2009Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks. Potential Mechanisms Beyond Nitric Oxide Synthase Inhibition. Arterioscler Thromb Vasc Biol Jun 18 (Epub ahead of print).
32. Lopez A,Lorente J,Steingrub JS,Bakker J,McLuckie A,et al. Year: 2004Multicenter, randomized, placebo-controlled double blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock.Crit Care Med32213014707556
33. Kielstein JT,Impraim B,Simmel S,Bode-Boger SM,Tsikas D,et al. Year: 2004Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans.Circulation10917217714662708
34. Richir MC,van Lambalgen AA,Teerlink T,Wisselink W,Bloemena E,et al. Year: 2009Low arginine/asymmetric dimethylarginine ratio deteriorates systemic hemodynamics and organ blood flow in a rat model.Crit Care Med372010201719384222
35. Vaughn MW,Kuo L,Liao JC. Year: 1998Effective diffusion distance of nitric oxide in the microcirculation.Am J Physiol274H170517149612383
36. Dondorp AM,Pongponratn E,White NJ. Year: 2004Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology.Acta Trop8930931714744557
37. Lowenstein CJ,Morrell CN,Yamakuchi M. Year: 2005Regulation of Weibel-Palade body exocytosis.Trends Cardiovasc Med1530230816297768
38. De Caterina R,Libby P,Peng HB,Thannickal VJ,Rajavashisth TB,et al. Year: 1995Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.J Clin Invest9660687542286
39. Hinder F,Stubbe HD,Van Aken H,Waurick R,Booke M,et al. Year: 1999Role of nitric oxide in sepsis-associated pulmonary edema.Am J Respir Crit Care Med1592522579872846
40. Bulau P,Zakrzewicz D,Kitowska K,Leiper J,Gunther A,et al. Year: 2007Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA.Am J Physiol Lung Cell Mol Physiol292L182416891395
41. Kielstein JT,Bode-Boger SM,Hesse G,Martens-Lobenhoffer J,Takacs A,et al. Year: 2005Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension.Arterioscler Thromb Vasc Biol251414141815860741
42. Nohria A,Gerhard-Herman M,Creager MA,Hurley S,Mitra D,et al. Year: 2006Role of nitric oxide in the regulation of digital pulse volume amplitude in humans.J Appl Physiol10154554816614356
43. Anthony S,Leiper J,Vallance P. Year: 2005Endogenous production of nitric oxide synthase inhibitors.Vasc Med10Suppl 1S3916444863
44. Karyana M,Burdarm L,Yeung S,Kenangalem E,Wariker N,et al. Year: 2008Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum.Malar J714818673572
45. Ratcliff A,Siswantoro H,Kenangalem E,Wuwung M,Brockman A,et al. Year: 2007Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.Trans R Soc Trop Med Hyg10135135917028048
46. Jones CE,Darcy CJ,Woodberry T,Anstey NM,McNeil YR. Year: 2010HPLC analysis of asymmetric dimethylarginine, symmetric dimethylarginine,homoarginine and arginine in small plasma volumes using a Gemini-NX column at high pH.Journal of Chromatography B Analyt Technol Biomed Life Sci878812

Figures

[Figure ID: ppat-1000868-g001]
doi: 10.1371/journal.ppat.1000868.g001.
Figure 1  Plasma dimethylarginine concentrations in each group on enrollment (ANOVA: p<0.001).

A. Plasma asymmetric dimethylarginine (ADMA) concentrations in each group on enrollment (ANOVA: p<0.001). In the severe malaria group, open circles represent fatal cases and closed circles survivors. Horizontal lines indicate mean for each group. B. Plasma symmetric dimethylarginine (SDMA) concentrations in each group on enrollment (ANOVA: p<0.001). In the severe malaria group, open circles represent fatal cases and closed circles survivors. Horizontal lines indicate mean for each group.



[Figure ID: ppat-1000868-g002]
doi: 10.1371/journal.ppat.1000868.g002.
Figure 2  Top panel is the nonparametric receiver operating curve (ROC) assessing asymmetrical dimethylarginine (AUROC, 0.85; 95%CI 0.71?0.99) and the bottom panel venous lactate (AUROC 0.63; 95%CI 0.41?0.83) as prognostic markers for mortality in severe malaria (p?=?0.003).

[Figure ID: ppat-1000868-g003]
doi: 10.1371/journal.ppat.1000868.g003.
Figure 3  Longitudinal course of plasma ADMA concentrations and L-arginine/ADMA ratio in patients with severe malaria.

Mean values (circles) and 95%CI (bars) are displayed at each time point. Values from day 5?14 indicate mean of all values obtained during this period. X axis values show time from start of anti-malarial therapy. Numbers indicate patients examined during each time period.



Tables
[TableWrap ID: ppat-1000868-t001] doi: 10.1371/journal.ppat.1000868.t001.
Table 1  Baseline Characteristics of Patients According to Clinical Status.
Healthy controls Moderately-severe malaria Severe malaria
Number 19 78 49
Age; mean (range), y 26 (18?40) 28 (18?56) 29 (18?56)
Males, No. (%) 13 (68) 32 (67) 36 (74)
Weight; mean (range), kg 60 (50?85) 58 (43?77) 57 (45?70)
Ethnicity, No. (%) Papuan highlander* 17 (89) 59 (77) 27 (55)
Current smoker, No. (%) 9 (47) 31 (40) 22 (45)
Days of fever before presentation; median (IQR)? Nil 2 (1?5) 4 (1?7)
Systolic blood pressure; mean (range), mmHg? 128 (112?138) 110 (80?134) 105 (60?154)
Pulse rate; mean (range), beats/minute? 67 (48?91) 81 (54?118) 98 (61?138)
Respiratory rate; mean (range), breaths/minute? 19 (18?23) 23 (16?32) 30 (16?60)
Temperature; mean (range), ?C? 35.6 (35.1?36.8) 36.5 (34.8?40.2) 37.2 (34.8?40.3)

* p<0.01 calculated by ?2 test.

? p<0.01 calculated by ANOVA or two sided t test.

IQR, interquartile range.


[TableWrap ID: ppat-1000868-t002] doi: 10.1371/journal.ppat.1000868.t002.
Table 2  Baseline Laboratory and Physiological Measurements According to Clinical Status.
Healthy controls Moderately-severe malaria Severe malaria
Number 19 78 49
White blood cell count; mean (95% CI), x 103?l?1* ND 5.9 (5.4?6.9) 9.5 (8.5?10.5)
Hemoglobin; mean (range), g/L* ND 121 (70?170) 109 (60?163)
Plasma cell-free hemoglobin; median (IQR), ?M? 1.3 (0.74?2.4) 2.6 (1.3?4.5) 5.4 (3.2?7.4)
Exhaled NO concentrations; median (IQR), ppb? 16.0 (9.5?19.3) 16.1 (10.7?25.3) 10.5 (7.5?15)
RH-PAT Index; mean (95%CI)* 1.87 (1.58?2.17) 1.82 (1.71?1.93) 1.37 (1.32?1.42)
Plasma creatinine; mean (95%CI), ?mol/L* ND 88 (82?94) 286 (207?365)
Plasma total bilirubin; mean (95%CI), ?mol/L* ND 16.7 (12.9?20.4) 95.2 (47.7?142.6)
Lactate concentration; mean (95%CI), mmol/L* ND 1.4 (1.2?1.6) 2.93 (2.3?3.5)
Parasite density, geometric mean (range), ?l?1* ND 14,900 (850?127,000) 35,100 (125?725,000)
HRP2 concentration; mean (range), loge ng/ml* ND 5.75 (1.34?8.79) 8.08 (1?10.98)
Soluble ICAM-1; mean (95%CI), pg/ml* ND 569 (516?623) 938 (792?1084)
Soluble E-selectin; mean (95%CI), pg/ml* ND 106 (95?118) 153 (113?193)
Plasma Angiopoietin-2; mean (95%CI), pg/ml* 2,800 (2,000?3,500) 6,500 (5,000?8,000) 17,000 (14,000?22,000)
Plasma ADMA; mean (95%CI), ?mol/L* 0.64 (0.58?0.70) 0.55 (0.5?0.56) 0.85 (74?0.96)
Plasma SDMA; mean (95%CI), ?mol/L* 0.53 (0.47?0.59) 0.58 (0.54?0.63) 1.67 (1.24?2.09)
Plasma L-arginine concentration; mean (95%CI) ?mol/L* 77 (65?88) 41 (37?44) 49 (43?56)
L-arginine/ADMA ratio; mean (95%CI)* 121 (107?135) 78 (71?86) 64 (56?71)
Plasma Arginase; mean (95%CI), ?mol/ml/h* 0.14 (0.08?0.17) 0.20 (0.14?0.24) 0.26 (0.22?0.31)

* p<0.01 calculated by ANOVA (overall) or two sided t test. ND, not measured.

? p<0.05 calculated by Kruskal-Wallis test.

IQR, Interquartile Range.


[TableWrap ID: ppat-1000868-t003] doi: 10.1371/journal.ppat.1000868.t003.
Table 3  Correlation Coefficients (Rs) for ADMA and Physiological Measures/Biomarkers of Severity.
All malaria patients Severe malaria
Correlation (rs) p df* Correlation (rs) p df*
ADMA RH-PAT Index ?0.32 0.001 139 ?0.22 0.18 48
Exhaled NO ?0.31 0.003 79 ?0.72 0.01 10
Lactate 0.30 0.01 124 0.1 0.3 48
HRP2 0.40 <0.001 109 0.42 0.004 44
ICAM-1 0.42 <0.001 109 0.61 <0.001 47
E-selectin 0.12 0.4 116 0.20 0.10 47
Ang-2 0.48 <0.001 140 0.56 <0.001 48
TNF 0.29 0.06 39
Creatinine 0.45 <0.001 117 0.55 <0.001 47
Total Bilirubin 0.32 <0.001 115 0.58 <0.001 47

*df?=?degrees of freedom.


[TableWrap ID: ppat-1000868-t004] doi: 10.1371/journal.ppat.1000868.t004.
Table 4  Factors Associated with Death in Severe Malaria Patients.
Risk Factors Univariate Model Final Model
Odds Ratio 95%CI P Odds Ratio 95%CI P
ADMA (?mol/L) 18.8 2.0?181 0.010 229 2.9?2675 0.025
Creatinine (?mol/L) 1.004 1.001?1.007 0.005 1.006 1.001?1.01 0.025
Angiopoietin 2 (pg/ml) 1.00058 1.00003?1.00109 0.024 1.00009 1.000002?1.0008 0.048
HRP2 (ng/ml) 1.00082 1.00009?1.001 0.01 1.0001 1.00002?1.002 0.017
Standard Base Deficit 1.19 1.01?1.4 0.037 0.93 0.64?1.35 0.659
Lactate (mmol/L) 1.32 1.02?1.41 0.044 1.29 0.51?3.3 0.485
Total Bilirubin (?mol/L) 1.006 1.001?1.009 0.015 1.003 0.98?1.1 0.21


Article Categories:
  • Research Article
Article Categories:
  • Immunology/Cellular Microbiology and Pathogenesis
  • Infectious Diseases/Protozoal Infections


Previous Document:  Independent component analysis in spiking neurons.
Next Document:  Proteolysis of human thrombin generates novel host defense peptides.